Pacira BioSciences, Inc. (PCRX)

Valuation on Pacira BioSciences, Inc. (PCRX) is stretched relative to sovereign debt yields, but short interest is too crowded to bet on immediate downside.

Secondary debt liquidity for PCRX proxies remains highly resilient despite headline noise. Watching gross margin expansion.

On our desk, the ongoing activist proxy battle led by DOMA Perpetual Capital Management creates a very specific governance overhang ahead of the June 2026 shareholder meeting. DOMA is aggressively calling out management and the board for historical underperformance and patent risk mismanagement regarding EXPAREL. While Frank Lee and his team are pushing forward with their '5x30' strategy—targeting metrics across patients served, product revenue, profitability, pipeline, and partnerships—institutional investors are sharply divided on whether leadership should remain independent or actively pursue a board-supervised sale process.

From a quantitative risk management perspective, the recent divestiture of iovera° has noticeably altered Pacira's balance sheet structure and required a revision of full-year 2026 guidance. Although the transaction successfully brings upfront capital and preserves upside through milestone payments to fund higher-value pharmaceutical programs, it also introduces near-term earnings recalibration. We are keeping a close eye on implied volatility across option chains to price in how the market digests these post-divestiture cash flows.

Looking at the Q2 2026 financial print, total revenue reached $192.4 million, representing a 6% year-over-year increase that beat Zacks consensus estimates, alongside an adjusted EPS of 73 cents. The company managed to swing back to profitability in the second quarter. However, with net income moderating earlier in the year and the 2026 sales outlook being adjusted following portfolio shifts, fundamental analysts must carefully parse the underlying organic volume growth of EXPAREL versus incremental revenues contributed by Zilretta.

As a hedge fund PM tracking specialty pharma, the core narrative on PCRX rests on whether the valuation discount is justified or if the market is severely underappreciating the long-term compounding of the '5x30' plan. Bulls emphasize that separate reimbursement codes are transforming EXPAREL from a single-product specialty line into a self-funded musculoskeletal pain platform. Conversely, bears point to activist letters arguing that management's historical total return to shareholders has been unacceptable, making governance risk a central pillar of any investment thesis here.

In our clinical workflow, the separate reimbursement mechanics rolling out for EXPAREL—specifically through the NOPAIN Act and UnitedHealthcare protocols—are fundamentally shifting institutional access and recurring protocol-based utilization. Real-world Medicare data highlighting reduced opioid use and lower overall medical costs following outpatient hip replacements provides a robust clinical justification for broader adoption. Clinicians are increasingly moving away from traditional opioid reliance when surgical pathways support non-opioid options backed by durable reimbursement.